Symptom burden of Australia and New Zealand (ANZ) patients with Neuroendocrine Tumours (NET)  (#348)

3:00 PM

David L Chan

Posters 2

‘Rethinking REAL-2: Real-life outcomes from an Australian retrospective audit of patients with metastatic oesophago-gastric adenocarcinoma (mOGC)’ (#219)

3:00 PM

Claudia E.A Stretch

Posters1

Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial (#268)

3:00 PM

Lorraine Chantrill

Posters1

A retrospective study of dual ¹⁸F-fluorodeoxyglucose/⁶⁸Gallium DOTATATE (FDG/⁶⁸Ga-DOTATATE) positron emission tomography (PET) grading and its prognostic value in metastatic pancreatic neuroendocrine tumours (PNET) (#349)

3:00 PM

David L Chan

Posters 2

Experience of Australia and New Zealand (ANZ) patients with neuroendocrine tumours (NET) treated at a NET specialist centre: Results of a national survey and the Royal North Shore experience (#350)

3:00 PM

David L Chan

Posters 2

NET Care in Australia; The patient’s perspective of their Neuroendocrine Tumours (NET) and impact of diagnosis (#374)

3:00 PM

John Leyden

Posters 2

ALK Translocated Non-Small Cell Lung Cancer: Experience from an Australian metropolitan tertiary referral centre. (#367)

3:00 PM

Malinda Itchins

Posters 2

Neuroendocrine tumor (NET) Oceania patient experience: results from the first global NET patient survey - A collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis (#74)

11:30 AM

John Leyden

Best of the Best Orals - Rare Cancers